Jess S. Morgan & Co’s NovoCure NVCR Stock Holding History

Jess S. Morgan & Co’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$3.73M	Buy	49,090 +745	+2%	+$58.1K	3.25%	11
2022 Q2	$3.36M	Sell	48,345 -515	-1%	-$38.8K	3.48%	12
2022 Q1	$4.05M	Buy	48,860 +4,885	+11%	+$360K	2.94%	16
2021 Q4	$3.3M	Buy	43,975 +10,695	+32%	+$1.07M	2.03%	29
2021 Q3	$3.87M	Buy	33,280 +9,505	+40%	+$1.44M	2.55%	30
2021 Q2	$5.27M	Sell	23,775 -2,207	-8%	-$429K	3.47%	3
2021 Q1	$3.43M	Sell	25,982 -2,250	-8%	-$356K	2.41%	26
2020 Q4	$4.88M	Sell	28,232 -4,800	-15%	-$657K	3.89%	2
2020 Q3	$3.68M	Sell	33,032 -2,910	-8%	-$233K	3.67%	3
2020 Q2	$2.13M	Sell	35,942 -5,837	-14%	-$384K	2.31%	31
2020 Q1	$2.81M	Sell	41,779 -11,110	-21%	-$878K	3.66%	7
2019 Q4	$4.46M	Buy	+52,889	New	+$4.27M	4.37%	3

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jess S. Morgan & Co's NVCR Position: Q3 2022 in Review

Jess S. Morgan & Co increased its NovoCure (NVCR) stake by 1.5% in Q3 2022, buying an estimated $58.1K and bringing the position to 49,090 shares worth $3.73M. The position accounts for 3.25% of the portfolio, ranked #11.

Jess S. Morgan & Co first reported a position in NVCR in Q4 2019 and has held it in 12 quarters since. The position peaked at $5.27M in Q2 2021. 304 funds tracked by Wall St. Rank hold NVCR as of Q3 2022.

Jess S. Morgan & Co held 49,090 shares of NovoCure worth $3.73M as of Q3 2022.
Jess S. Morgan & Co bought 745 NovoCure shares in Q3 2022, an estimated $58.1K.
NovoCure made up 3.25% of Jess S. Morgan & Co's portfolio in Q3 2022, its #11 holding.
Jess S. Morgan & Co first reported a position in NovoCure in Q4 2019 and has held it in 12 quarters since.
Jess S. Morgan & Co's NovoCure position peaked at $5.27M in Q2 2021.
304 funds tracked by Wall St. Rank held NovoCure as of Q3 2022.

Based on Jess S. Morgan & Co's 13F filing for Q3 2022, filed 21 Oct 2022.